Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial. // The Lancet Rheumatology. – URL: https://www.sciencedirect.com/science/article/pii/S2665991326002523?dgcid=rss_sd_all
Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial. The Lancet Rheumatology. https://www.sciencedirect.com/science/article/pii/S2665991326002523?dgcid=rss_sd_all
“Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial.” The Lancet Rheumatology.
@article{article69294,
title = {Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial},
journal = {The Lancet Rheumatology},
url = {https://www.sciencedirect.com/science/article/pii/S2665991326002523?dgcid=rss_sd_all}
}